A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
While dismissing some claims, U.S. District Judge Jesse Furman in Manhattan said the plaintiff UMB Bank may pursue some claims on behalf of the shareholders, including for breach of contract.
(Reporting by Stempel in New York; Editing by Chris Reese)
Copyright 2026 Reuters. Click for restrictions.
Was this article valuable?
Here are more articles you may enjoy.
BofA Agrees to Settle Claims It Aided Epstein Sex Crimes 
DoorDash’s New Paid Tasks Turn Couriers into AI and Robot Trainers 
‘Nation’s First’ Smoke Damage Standards Bill Making Its Way Through California Legislature 
Study Shows Consumer Willingness to Edit Claim Images 
Want to stay up to date?
Get the latest insurance news
sent straight to your inbox.